Recent results raise hope of new "broad, pan-tumor platform" like Keytruda. The emerging drugs are bispecific antibodies that ...

The new $467 million includes $400 million in royalties for the Pfizer-BioNTech vaccine from 2020 through 2023.

After the University of Pennsylvania and the U.S. National Institutes of Health (NIH) separately pressed BioNTech for royalties on its Pfizer-partnered COVID-19 vaccine Comirnaty, the German ...

Atomi Financial Group Inc. raised its stake in BioNTech SE (NASDAQ:BNTX – Free Report) by 6.7% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional ...

“Pairing BioNTech’s deep knowledge of the human immune system and scientific data-driven development approach with our AI platform could transform the way we discover and develop new drug ...

Penn sued BioNTech in August alleging the university was owed more in royalty payments for the use of the university's patented technology in a Covid-19 vaccine. BioNTech has agreed to pay the ...

German pharmaceutical company BioNTech has agreed to pay a combined sum of more than $1.2 billion to resolve separate disputes over royalty payments related to its COVID-19 vaccine. https://p.dw ...

The Nobel Prize-winning scientific innovation underlying the ... $467 million under a settlement with German drug manufacturer BioNTech, which partnered with Pfizer to develop a COVID vaccine ...